Advanced SearchSearch Tips
Resistin and Insulin Resistance: A Link Between Inflammation and Hepatocarcinogenesis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Resistin and Insulin Resistance: A Link Between Inflammation and Hepatocarcinogenesis
Elsayed, Engy Yousry; Mosalam, Nesreen Ahmed; Mohamed, Noha Refaat;
  PDF(new window)
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer related death overall. The role of insulin resistance in the development of HCC associated with chronic HCV infection has not been established. Resistin is a polypeptide hormone belonging to the adipokine family which could contribute to tumorigenesis and angiogenesis. Our aim was to study serum resistin and insulin resistance as risk factors for HCC in HCV cirrhotic patients. Materials and Methods: This prospective case controlled study included 100 patients with HCV related liver cirrhosis and HCC, 100 patients with HCV related liver cirrhosis without HCC and 50 apparently healthy participants as controls. For all subjects, liver profile, serologic markers for viral hepatitis, lipid profile, alpha-fetoprotein level (AFP), homeostasis model assessment (HOMA) were examined along with resistin. Results: HCC patients had higher mean values of HOMA-IR and resistin than cirrhotic patients and the control subjects (p<0.01). HOMA and resistin were considered independent risk factors in development of HCC, those patients with resistin > 12 ng/ml and HOMA > 4 being 1.6 times more likely to have HCC. Conclusions: HOMA and serum resistin allow for early identification of patients with cirrhosiswho are at substantially increased risk of HCC. Recommendation: HOMA and serum resistin could represent novel markers to identify HCV cirrhotic patients at greater risk of development of HCC.
Resistin;insulin resistance;HOMA IR;hepatocellular carcinoma;
 Cited by
Resistin aggravates the expression of proinflammatory cytokines in cerulein-stimulated AR42J pancreatic acinar cells, Molecular Medicine Reports, 2016, 15, 1, 502  crossref(new windwow)
Alexia C, Fallot G, Lasfer M, et al., (2004). An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogene-sisand in the resistance of hepatocarcinoma cells against drug induced apoptosis. Bi-ochem Pharmacol, 68, 1003-15. crossref(new window)

Bota S, Piscaglia F, Bolondi L (2012). Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver cancer, 13, 190-200.

Bertolani C, Sancho-Bru P, Failli P, et al (2006). Resistin as an Intrahepatic Cy-tokine: overexpression during chronic injury and induction of proinflammatory ac-tions in hepatic stellate cells. Am J Pathol, 169, 2042-2053. crossref(new window)

Cowey S, Hardy RW (2006). The Metabolic syndrome: a high risk state for can-cer? Am J Pathol, 169, 1505-22. crossref(new window)

Dailey G(2004) : New strategies for basal insulin treatment in type 2 diabetes melli-tus. Clin Ther, 26, 889-901. crossref(new window)

Dalamaga M, Sotiropoulos G, Karmaniolas K, et al., (2013). Serum resistin: a bi-omarker of breast cancer inpostmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem, 46, 584-590. crossref(new window)

Diehl AM(2002). Nonalcoholic steatosis and steatohepatitis. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol, 282, 1-5. crossref(new window)

Donadon V, Balbi M, Zanette G (2009). Hyperinsulinemia and risk for hepatocel-lular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus. Expert Rev Gastroenterol Hepatol, 3, 465-7. crossref(new window)

El-Zayadi A-R, Anis M (2012). Hepatitis C virus in-duced insulin resistance impairs response to anti viral therapy. World J Gastroenterol, 18, 212-24. crossref(new window)

Eslam M, Khattab MA, Harrison SA ( 2011). Insulin resistance and hepatitis C: An evolving story. Gut, 60, 1139-51 crossref(new window)

Fartoux L, Poujol-Robert A, Guechot J, et al. ( 2005). Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut, 54, 1003-8. crossref(new window)

Gomaa AA, Helmy AM, El Fayuomy KN, et al (2010). Role of insulin re-sistance in the development of hepatocellularcarcinoma in patients with chronic hepa-titis C. AAMJ, 8, 294-313.

Housa D, Housova J, Vernerova Z, et al (2006). Adipocytokines and cancer. Physiol Res, 55, 233-44.

Hsu WY, Chao YW, Tsai YL, et al (2011). Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothe-lial cells via p38MAPKdependent pathway. J Cell Physiol, 226, 2181-8. 45. crossref(new window)

Hui-Qi Qu, Quan Li, Anne R. Rentfro, et al (2011). The definition of insulin resistance using HOMA-IR for americans of mexican descent using machine learning. PLoS One, 6, 21041. crossref(new window)

Hung CH, Wang JH, Hu TH, et al (2010). Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol, 16, 2265-71. crossref(new window)

Irshad M, Iqbal A, Ansari MA, et al (2013). Relation of insulin resistance (IR) with viral etiology and blood level of cytokines in patients with liver diseases. Glo Adv Res J Med Med Sci, 2, 75-83.

Jansson SP, Andersson DK and Svardsudd K (2010). Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care, 33, 551-556. crossref(new window)

Kakizaki S, Sohara N, Yamazaki Y, et al (2008). Elevated plasma resistin con-centrations in patients with liver cirrhosis. J Gastroenterol Hepatol, 23, 73-7. crossref(new window)

Kawaguchi T, Taniguchi E, Itou M, et al (2011). Insulin resistance and chronic liver disease. World J Hepatol, 3, 99-107. crossref(new window)

Kawaguchi T, Taniguchi E, Morita Y, et al (2010). Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in pa-tients with hepatitis C virus infection. Liver Int, 30, 479-86. crossref(new window)

Martin Kopa, Jana Muchova, Zdenka Durac kova (2013). Modulation of insulin resistance by PUFA in metabolic tissues Eur. J Lipid Sci Technol, 115, 475-482. crossref(new window)

Mohamed AA, Loutfy SA, Craik JD, et al (2011). Chronic hepatitis C genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol, 8, 496. crossref(new window)

Mohamed FS, El-Bardiny M, Abdel-Moety AA. et al (2014). Assessment of in-sulin resistance, serum adiponectin and ferritin levels in HCC patients before and af-ter radiofrequency ablation. JMSCR, 2, 1065-83.

Nkontchouemail G, Bastard J, Ziol M, et al (2010). Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol, 53, 827-33. crossref(new window)

Yagmur E, Trautwein C, Gressner AM, et al (2006). Resistin serum levels are associated with insulinresistance, disease severity, clinical complications, and prog-nosis in patients with chronic liver diseases. Am J Gastroenterol, 101, 1244-52. crossref(new window)

Yang CC, Chang SF, Chao JK, et al (2014). Activation of AMPactivated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin. BMC Cancer, 14, 112-20. crossref(new window)